FDA Accepts Supplemental NDA for REZDIFFRA (Resmetirom) by Madrigal
The FDA has accepted a supplemental NDA for REZDIFFRA, indicating progress in its regulatory pathway.
Company
Pharmaceutical intelligence for Madrigal Pharmaceuticals with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.